Estimaciones de analistas de Wall Street para NuCana plc (NCNA): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 7 |
| Mantener | 1 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 8 |
| Calificación media (1-5) | 0.88 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-2.69 | ||
| 2026-08-13 | $-0.99 | $-2.65 | +62.7% |
| 2026-05-14 | $-1.25 | $-2.64 | +52.7% |
| 2026-03-19 | $-1.47 | $-2.69 | +45.4% |
| 2025-11-13 | $-0.10 | $-2.69 | +96.3% |
| 2025-08-20 | $-0.16 | $-2.75 | +94.2% |
| 2025-06-03 | $-5.17 | $-0.01 | -51560.0% |
| 2025-03-20 | $-64.00 | $-486.00 | +86.8% |
Ratios de valoración
| Precio / Valor contable | 0.23 |
| EV / EBITDA | 0.85 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | $283000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | $283000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $7.9M | $17.7M | $16.8M | $19.7M | $25.9M | $36.8M | $36.4M | $25.1M | $18.0M | $12.7M |
| Generales y Administrativos | $1.1M | $4.6M | $5.2M | $6.0M | $7.0M | $8.5M | $7.3M | $6.1M | $5.0M | $8.1M |
| Gastos Operativos | $9.0M | $24.0M | $22.0M | $25.7M | $32.9M | $47.9M | $39.1M | $32.8M | $22.8M | $20.1M |
| Beneficio Operativo | -$8.4M | -$22.2M | -$22.0M | -$26.7M | -$36.4M | -$47.9M | -$39.1M | -$32.8M | -$22.8M | -$20.1M |
| EBITDA | -$8.9M | 0 | 0 | 0 | -$28.6M | -$44.4M | -$43.0M | -$30.6M | -$22.5M | -$20.6M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$8.2M | -$25.5M | -$18.1M | -$25.7M | -$36.2M | -$47.8M | -$38.5M | -$32.0M | -$22.5M | -$30.5M |
| Impuestos | -$2.1M | -$2.4M | -$4.2M | -$4.2M | -$5.5M | -$7.3M | -$6.4M | -$4.4M | -$3.5M | -$1.2M |
| Beneficio Neto | -$6.0M | -$23.1M | -$13.8M | -$21.4M | -$30.7M | -$40.5M | -$32.0M | -$27.6M | -$19.0M | -$29.4M |
| BPA | $1359.22 | $-4747.43 | $-2886.02 | $-4224.99 | $-5193.15 | $-5355.91 | $-3775.53 | $-3266.68 | $-1635.98 | $-17.20 |
| BPA Diluido | $1359.22 | $-4747.43 | $-2886.02 | $-4224.99 | $-5193.15 | $-5355.91 | $-3775.53 | $-3266.68 | $-1635.98 | $-17.20 |
| Acciones en Circulación (Diluidas) | $6362 | $6262 | $6394 | $6465 | $7576 | $10408 | $10447 | $10514 | $14838 | $2.2M |
Precio
| Precio | $1.30 |
| Capitalización | $8M |
| Bolsa | NASDAQ |
| País | GB |
Empresas relacionadas: CASI · CLGN · CLSD · ENLV · GDTC · LSTA · MTVA
Explorar sector: Healthcare · Biotechnology
Más secciones de NCNA: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones